NRXP NRX Pharmaceuticals, Inc.
$3.40▲ +0.00%
Healthcare
Other
After hours
$3.43▲ +0.78%
Sep 11, 7:30 PM ET
Volume 350.7K
Avg Volume (10D) 493.4K
Key Metrics & Fundamentals
Market Cap
$147.21M
P/E Ratio
–
Div Yield
–%
52W Range
1.62 - 5.06
% vs 50 MA
-6.59%
% vs 200 MA
18.34%
RSI-14
46.4
MACD Histogram
+0.0000
Beta (1Y vs SPY)
2.09
Free Cash Flow
-$9.77M
Gross Rev
$1.10M
Gross Profit
$426,000
EBITDA
-$6.32M
COGS
$675,000
Operating Exp
$6.93M
Operating Income
-$6.50M
EBIT
-$6.50M
Pretax Income
-$16.52M
Net Income
-$16.52M
EPS (Diluted)
-0.44
Price & Volume History
Loading chart…
Recent News
NRX Pharmaceuticals' HOPE Therapeutics to Deploy Zeta's TMS Robotic System
MT Newswires · Sep 11, 2026 11:32 AM
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System
GlobeNewswire · Sep 11, 2026 11:00 AM
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire · Sep 8, 2026 11:00 AM
NRx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 18, 2026 12:30 PM
NRX Pharmaceuticals Inc (NRXP) (Q2 2026) Earnings Call Highlights: Advancing Ketamine Pipeline ...
GuruFocus.com · Aug 18, 2026 5:02 AM
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Market Exclusive · Aug 17, 2026 7:26 PM
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
GlobeNewswire · Aug 17, 2026 11:00 AM
NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates
Zacks · Aug 15, 2026 12:15 AM
NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles
MarketBeat · Aug 10, 2026 2:04 PM
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
GlobeNewswire · Aug 7, 2026 8:01 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See NRXP's money flow as a full page
Social Sentiment
Avg +0.60 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.